Immunocore (IMCR) Competitors $31.93 -0.17 (-0.53%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$32.24 +0.31 (+0.99%) As of 08/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCR vs. RYTM, NUVL, TGTX, AXSM, LNTH, CRSP, ADMA, ABVX, MRUS, and KRYSShould you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Rhythm Pharmaceuticals (RYTM), Nuvalent (NUVL), TG Therapeutics (TGTX), Axsome Therapeutics (AXSM), Lantheus (LNTH), CRISPR Therapeutics (CRSP), ADMA Biologics (ADMA), Abivax (ABVX), Merus (MRUS), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Immunocore vs. Its Competitors Rhythm Pharmaceuticals Nuvalent TG Therapeutics Axsome Therapeutics Lantheus CRISPR Therapeutics ADMA Biologics Abivax Merus Krystal Biotech Immunocore (NASDAQ:IMCR) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment. Which has more volatility and risk, IMCR or RYTM? Immunocore has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Do analysts prefer IMCR or RYTM? Immunocore presently has a consensus target price of $58.89, indicating a potential upside of 84.43%. Rhythm Pharmaceuticals has a consensus target price of $101.57, indicating a potential upside of 9.83%. Given Immunocore's higher possible upside, research analysts clearly believe Immunocore is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunocore 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07 Do institutionals & insiders have more ownership in IMCR or RYTM? 84.5% of Immunocore shares are owned by institutional investors. 10.4% of Immunocore shares are owned by insiders. Comparatively, 6.1% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media favor IMCR or RYTM? In the previous week, Rhythm Pharmaceuticals had 11 more articles in the media than Immunocore. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 6 mentions for Immunocore. Immunocore's average media sentiment score of 1.03 beat Rhythm Pharmaceuticals' score of 0.73 indicating that Immunocore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Is IMCR or RYTM more profitable? Immunocore has a net margin of -6.48% compared to Rhythm Pharmaceuticals' net margin of -117.13%. Immunocore's return on equity of -5.86% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Immunocore-6.48% -5.86% -2.09% Rhythm Pharmaceuticals -117.13%-1,831.43%-48.33% Which has higher earnings and valuation, IMCR or RYTM? Immunocore has higher revenue and earnings than Rhythm Pharmaceuticals. Immunocore is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunocore$310.20M5.17-$51.09M-$0.43-74.26Rhythm Pharmaceuticals$130.13M45.21-$260.60M-$3.01-30.72 SummaryImmunocore beats Rhythm Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCR vs. The Competition Export to ExcelMetricImmunocoreMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.61B$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-74.2517.9729.8525.14Price / Sales5.17262.52422.3397.16Price / CashN/A41.8335.9458.58Price / Book4.437.238.125.59Net Income-$51.09M-$54.43M$3.26B$265.48M7 Day Performance-3.21%0.22%0.68%1.22%1 Month Performance-4.06%5.59%2.46%0.39%1 Year Performance-15.80%9.98%27.99%23.47% Immunocore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCRImmunocore1.7499 of 5 stars$31.93-0.5%$58.89+84.4%-13.5%$1.61B$310.20M-74.25320News CoveragePositive NewsEarnings ReportHigh Trading VolumeRYTMRhythm Pharmaceuticals3.5698 of 5 stars$90.24+2.2%$91.93+1.9%+112.3%$5.62B$130.13M-32.11140Earnings ReportAnalyst ForecastNUVLNuvalent3.1474 of 5 stars$78.35+0.8%$119.60+52.6%+7.0%$5.58BN/A-17.8540Upcoming EarningsTGTXTG Therapeutics4.0201 of 5 stars$28.72-18.0%$43.80+52.5%+39.5%$5.56B$329M119.67290Trending NewsEarnings ReportAnalyst RevisionHigh Trading VolumeAXSMAxsome Therapeutics4.8393 of 5 stars$106.54+3.4%$172.33+61.8%+24.4%$5.07B$385.69M-18.46380Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionLNTHLantheus4.6129 of 5 stars$71.46+1.3%$131.20+83.6%-42.9%$4.88B$1.53B20.30700Trending NewsEarnings ReportAnalyst ForecastCRSPCRISPR Therapeutics3.6797 of 5 stars$59.59+6.2%$70.07+17.6%+18.4%$4.84B$37.31M-13.18460Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionADMAADMA Biologics4.2961 of 5 stars$19.91+3.0%$27.67+39.0%+46.3%$4.61B$426.45M23.42530Trending NewsEarnings ReportGap DownABVXAbivax3.476 of 5 stars$72.07+0.2%$92.33+28.1%+521.8%$4.57BN/A0.0061Upcoming EarningsMRUSMerus3.0155 of 5 stars$66.93+2.1%$86.40+29.1%+29.4%$4.54B$36.13M-16.4037Positive NewsEarnings ReportAnalyst ForecastKRYSKrystal Biotech4.814 of 5 stars$134.94-14.0%$211.33+56.6%-22.1%$4.54B$290.52M32.44210Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies RYTM Competitors NUVL Competitors TGTX Competitors AXSM Competitors LNTH Competitors CRSP Competitors ADMA Competitors ABVX Competitors MRUS Competitors KRYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCR) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
